BioRadar Blog
Biotech trading insights, PDUFA analysis, and market intelligence.
What a New 2,610-Patient AML Registry Study Does and Does Not Tell Us About SELLAS’s REGAL Control Arm
A 2,610-patient PETHEMA registry study shows how venetoclax and HMA therapy fare in real-world AML, and what it does not tell us about SELLAS's REGAL trial.
Read article →Inovio’s VOCERYQ (INO-3107) Accelerated Approval: What the FDA Decided and What Comes Next
The FDA granted Inovio's VOCERYQ (INO-3107) accelerated approval on Oct 30, 2026. The label, the required confirmatory study, Papzimeos and the $80.5M raise.
Read article →Biotech Catalysts This Week: 1 Trial Completion and 10 New Financings (Oct 4-11, 2026)
Biotech catalysts, Oct 4 to Oct 11, 2026: no FDA decision dates, 1 Phase 2 or 3 trial reaching primary completion and 10 new financing filings.
Read article →Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Sep 27–Oct 4, 2026)
No FDA decision dates fall in this week, so the calendar belongs to trials: seven company-led studies have estimated primary completion dates, among them IBRX’s BCG combination in bladder cancer,…
Read article →Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Sep 20–Sep 27, 2026)
Here’s what’s on the biotech calendar for September 20–September 27: 2 FDA decision dates, 1 trial catalysts, and 0 earnings reports from tracked companies. 💊 FDA Decisions (PDUFA Dates) Date…
Read article →Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Sep 13–Sep 20, 2026)
Here’s what’s on the biotech calendar for September 13–September 20: 1 FDA decision dates, 2 trial catalysts, and 0 earnings reports from tracked companies. 💊 FDA Decisions (PDUFA Dates) Date…
Read article →The Ghost PDUFA Date: Zidesamtinib Was Approved Two Months Early, After Nuvalent Was Already Sold
The September 18, 2026 PDUFA date on many calendars is a ghost: GSK closed its Nuvalent buyout on July 15 and the FDA approved zidesamtinib on July 22. What calendar…
Read article →Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Sep 6–Sep 13, 2026)
No FDA decision dates or earnings reports fall in this week. The nearest regulatory events on the Run-up Radar are NUVL’s NDA decision in 12 days and MIRM’s in 20…
Read article →Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Aug 30–Sep 6, 2026)
Here’s what’s on the biotech calendar for August 30–September 6: 0 FDA decision dates, 15 trial catalysts, and 0 earnings reports from tracked companies. 🧪 Trial Catalysts & Milestones APGE,…
Read article →Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Aug 23–Aug 30, 2026)
Here’s what’s on the biotech calendar for August 23–August 30: 2 FDA decision dates, 4 trial catalysts, and 1 earnings reports from tracked companies. 💊 FDA Decisions (PDUFA Dates) Date…
Read article →